A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women - 12/11/11
Abstract |
Background |
Although twice-daily application of propylene glycol–containing 2% minoxidil topical solution (MTS) stimulates new hair growth, higher concentrations of minoxidil in a once-daily, propylene glycol–free formulation may improve efficacy and reduce unpleasant side effects.
Objective |
We sought to compare the efficacy, safety, and acceptability and to show noninferiority of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% MTS in women with androgenetic alopecia.
Methods |
A total of 113 women with androgenetic alopecia were randomized to 24 weeks of treatment with 5% MTF or 2% MTS. The primary efficacy parameter was change from baseline in nonvellus target area hair count at week 24. Secondary end points included change in nonvellus target area hair width, overall efficacy by global photographic review as assessed by treatment-blinded evaluators and the subject herself, adverse events, and participants’ assessment of product aesthetics.
Results |
After 24 weeks, women randomized to 5% MTF once daily showed noninferior target area hair count and target area hair width and experienced greater, but nonsignificant, improvements in target area hair count, target area hair width, and overall efficacy by global photographic review than those randomized to 2% MTS used twice daily. 5% MTF was significantly superior to 2% MTS in participants’ agreement with “the treatment does not interfere with styling my hair” (P = .002). Women randomized to 5% MTF experienced significantly lower rates of local intolerance (P = .046) especially in pruritus and dandruff compared with 2% MTS.
Limitation |
Because of differences in the formulations tested, study participants were not blinded to treatment.
Conclusions |
Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantages.
Le texte complet de cet article est disponible en PDF.Key words : androgenetic alopecia, female pattern hair loss, hair preparations, hypertrichosis, minoxidil, topical administration, topical foam, topical solution
Abbreviations used : AE, AGA, GPR, LI, MTF, MTS, TAHC, TAHW
Plan
The first two authors contributed equally to the study and preparation of this manuscript. |
|
Supported by a medical grant application, Johnson & Johnson Consumer Co Inc. |
|
Disclosure: Dr Blume-Peytavi is a consultant for Johnson & Johnson Consumer Co Inc. Dr Garcia Bartels was a consultant for Pfizer GmbH Germany until 2008. Dr Hillmann, Dr Dietz, and Mr Canfield have no conflicts of interest to declare. |
Vol 65 - N° 6
P. 1126 - décembre 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?